EP1324763A4 - Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci - Google Patents

Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Info

Publication number
EP1324763A4
EP1324763A4 EP01970740A EP01970740A EP1324763A4 EP 1324763 A4 EP1324763 A4 EP 1324763A4 EP 01970740 A EP01970740 A EP 01970740A EP 01970740 A EP01970740 A EP 01970740A EP 1324763 A4 EP1324763 A4 EP 1324763A4
Authority
EP
European Patent Office
Prior art keywords
antagonists
therapeutic uses
stat3
agonists
stat3 agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01970740A
Other languages
German (de)
English (en)
Other versions
EP1324763A1 (fr
Inventor
Hua Yu
Drew Pardoll
Richard Jove
William Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Johns Hopkins University
Original Assignee
University of South Florida
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, Johns Hopkins University filed Critical University of South Florida
Publication of EP1324763A1 publication Critical patent/EP1324763A1/fr
Publication of EP1324763A4 publication Critical patent/EP1324763A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01970740A 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci Withdrawn EP1324763A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23121200P 2000-09-08 2000-09-08
US231212P 2000-09-08
PCT/US2001/028254 WO2002020032A1 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Publications (2)

Publication Number Publication Date
EP1324763A1 EP1324763A1 (fr) 2003-07-09
EP1324763A4 true EP1324763A4 (fr) 2007-10-31

Family

ID=22868214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01970740A Withdrawn EP1324763A4 (fr) 2000-09-08 2001-09-10 Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci

Country Status (3)

Country Link
EP (1) EP1324763A4 (fr)
CA (1) CA2421723A1 (fr)
WO (1) WO2002020032A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1146869A2 (fr) 1999-01-27 2001-10-24 University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2006065894A2 (fr) 2004-12-14 2006-06-22 University Of South Florida Procedes pour inhiber la signalisation stat3 dans des cellules immunitaires
WO2010118309A2 (fr) 2009-04-10 2010-10-14 Board Of Regents, The University Of Texas System Inhibiteurs du stat3 et leurs utilisations
CN109890965A (zh) * 2016-07-19 2019-06-14 匹兹堡大学联邦系统高等教育 靶向stat3的溶瘤病毒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044774A2 (fr) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition de la transduction du signal par la stat3 pour une therapie anticancereuse chez l'homme

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NEGORO, S. ET AL.: "Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction", CARDIOVASCULAR RESEARCH, vol. 47, 6 September 2000 (2000-09-06), pages 797 - 805, XP002448915 *
NEGORO, S. ET AL.: "Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxigenation-induced oxidative stress through the upregulation of manganese superoxide dismutase", CIRCULATION, vol. 104, 28 August 2001 (2001-08-28), pages 979 - 981, XP002448916 *
See also references of WO0220032A1 *
YAMAUCHI-TAKIHARA, K. & KISHIMOTO, T.: "A novel role for STAT3 in cardiac remodeling", TRENDS IN ARDIOVASCULAR MEDICINE, vol. 10, no. 7, October 2000 (2000-10-01), pages 298 - 303, XP002448914 *

Also Published As

Publication number Publication date
CA2421723A1 (fr) 2002-03-14
WO2002020032A9 (fr) 2003-03-20
EP1324763A1 (fr) 2003-07-09
WO2002020032A1 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
IL150898A0 (en) Novel melanocortin receptor agonists and antagonists
IL159015A0 (en) Polypeptides, their preparation and use
PL366233A1 (en) Substituted pyridoindoles as serotonin agonists and antagonists
IL150632A0 (en) Corticotropin releasing factor antagonists
HK1060727A1 (en) Antagonists of mcp-1 function and methods of use thereof
IL153181A0 (en) Glucagon antagonists/inverse agonists
PT1379504E (pt) Derivados bipiperidinilo e sua utilização como inibidores de receptores de quimioquinas
HUP0302126A3 (en) Anthranyl amides and their use as medicaments
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HK1060728A1 (en) Antagonists of mcp-1 function and methods of use thereof
HUP0500989A2 (en) Animicrobial polypeptides and their uses
GB0101035D0 (en) Formulation and use thereof
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HK1069385A1 (en) Heterocyclic compound and medicinal use thereof
IL158397A0 (en) Polypeptides, their preparation and their use
IL159872A0 (en) Gmg-2 polypeptides and their use
HUP0401535A3 (en) Somatostatin antagonists and their use
AU9275001A (en) Notch receptor agonists and uses
EP1324763A4 (fr) Agonistes et antagonistes de stat3 et applications therapeutiques de ceux-ci
HUP0301384A3 (en) Urotensin-ii agonists and antagonists
EP1241257A4 (fr) Polypeptides de type tachykinine et utilisation associee
GB0018887D0 (en) Compound and their therapeutic use
EP1367123A4 (fr) Neurotonine et utilisation
AU2003300396A8 (en) Chemokine antagonists and uses thereof
GB2377179B (en) Magnotherapy device and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030407

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHN HOPKINS UNIVERSITY

Owner name: UNIVERSITY OF SOUTH FLORIDA

A4 Supplementary search report drawn up and despatched

Effective date: 20071001

17Q First examination report despatched

Effective date: 20081020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057172

Country of ref document: HK